Literature DB >> 2920097

Does chronic hyperinsulinemia cause hypertension?

J E Hall1, T G Coleman, H L Mizelle.   

Abstract

The aim of this study was to determine whether chronic hyperinsulinemia, comparable to that found in obesity-associated hypertension, causes sustained increases in mean arterial pressure (MAP) or potentiates the hypertensive effects of angiotensin II (ANG II). Insulin infusion (0.5 or 1.0 mU/kg/min, IV), with plasma glucose held constant by IV glucose infusion, for seven to 28 days raised plasma insulin by five- to ten-fold, but did not significantly change MAP in dogs with reduced kidney mass that were maintained on high sodium intake. In dogs infused with ANG II to cause mild hypertension, insulin for 28 days did not potentiate the hypertension. Insulin infusion did, however, cause modest sodium retention during the first few days of infusion. These findings suggest that additional factors besides hyperinsulinemia per se are responsible for obesity-associated hypertension.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2920097     DOI: 10.1093/ajh/2.3.171

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  5 in total

1.  Hyperinsulinaemia is not linked with blood pressure elevation in patients with insulinoma.

Authors:  P T Sawicki; L Heinemann; A Starke; M Berger
Journal:  Diabetologia       Date:  1992-07       Impact factor: 10.122

Review 2.  Role of Hyperinsulinemia and Insulin Resistance in Hypertension: Metabolic Syndrome Revisited.

Authors:  Alexandre A da Silva; Jussara M do Carmo; Xuan Li; Zhen Wang; Alan J Mouton; John E Hall
Journal:  Can J Cardiol       Date:  2020-02-12       Impact factor: 5.223

Review 3.  Nutritional and endocrine modulation of intracellular calcium: implications in obesity, insulin resistance and hypertension.

Authors:  M B Zemel
Journal:  Mol Cell Biochem       Date:  1998-11       Impact factor: 3.396

4.  Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholytic agent.

Authors:  P Ernsberger; R J Koletsky; L A Collins; D Bedol
Journal:  Cardiovasc Drugs Ther       Date:  1996-06       Impact factor: 3.727

5.  Reduced ENaC activity and blood pressure in mice with genetic knockout of the insulin receptor in the renal collecting duct.

Authors:  Lijun Li; R Mayuri Garikepati; Susanna Tsukerman; Donald Kohan; James B Wade; Swasti Tiwari; Carolyn M Ecelbarger
Journal:  Am J Physiol Renal Physiol       Date:  2012-11-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.